You are here: Industry Insights > Lonza

News List

Lonza Expands API Development, Mfg. Facility in China contractpharma
June 29, 2021
Lonza is investing CHF 20 million in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China.
CellPoint and Lonza Enter Strategic Collaboration contractpharma
June 25, 2021
CellPoint has signed an agreement with Lonza's Personalized Medicine Business Unit to employ Lonza's Cocoon Platform for clinical manufacturing of CellPoint's CAR-T cell therapies at the point-of-care, more rapidly and at lower cost.
Moderna enters drug substance production deal with Lonza pharmaceutical-technology
June 04, 2021
Moderna has signed a new agreement with Lonza to create a new production line at the latter’s Geleen facility in the Netherlands, which will support drug substance production for its international supply chain.
Lonza to install new production line at Geleen to increase Moderna COVID-19 vaccine output by 300 million doses per year cphi-online
June 03, 2021
Drug substance production line expected to be operational by end of 2021 as part of CDMO’s expanded collaboration with biotech
Lonza, Moderna Expand COVID Vax Mfg. Alliance contractpharma
June 03, 2021
Lonza to support the manufacture of up to an additional 300 million doses per year with install of a new manufacturing line at The Netherlands site.
Lonza Announces Expansion Plans for Next-Generation Mammalian Manufacturing Facilities in Visp (CH) and Portsmouth (US) americanpharmaceuticalreview
May 07, 2021
Lonza has announced significant investments to expand its mammalian drug substance manufacturing facilities in Visp (CH) and Portsmouth (US).
Moderna to Increase Global Supply for COVID-19 Vaccine contractpharma
May 06, 2021
Moderna has unveiled plans for new funding commitments to increase supply at its owned and partnered manufacturing facilities, which it expects will increase global 2022 capacity to up to 3 billion doses of its COVID-19 vaccine, depending upon the ...
Lonza Doubles Drug Substance Production for Moderna’s COVID-19 Vaccine contractpharma
April 30, 2021
Lonza has expanded its collaboration with Moderna to manufacture the drug substance for the biopharma’s COVID-19 vaccine.
Lonza to Build Small Molecule Manufacturing Complex in Visp contractpharma
April 25, 2021
Lonza, a contract development and manufacturing organization (CDMO) partner to the biopharma industry, is investing CHF 200 million (~$220mn) in the construction of a new small molecule manufacturing complex at its Visp site in Switerland.
Lonza Expands PyroTec PRO for Endotoxin Testing contractpharma
April 13, 2021
Lonza has expanded its PyroTec PRO Automated Robotic Solution for endotoxin testing. The new PyroWave Reader add-on has been designed specifically for use with the sustainable PyroGene Recombinant Factor C (rFC) Assay.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page